Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Reims has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter involves 1 distinct examiner and 1 distinct art unit. The company's active prosecution is currently focused on this single technical matter.
GALSTER, SAMUEL LEONARD is the busiest examiner, responsible for 1 pending office action. Since this is the only pending office action for the company, GALSTER, SAMUEL LEONARD is the sole point of contact for active examination. This concentration simplifies the management of deadlines and the preparation of technical responses.
The 1 distinct art unit assigned to this matter indicates a specialized examination environment. Having 1 distinct examiner means that the company can focus its resources on addressing the specific requirements of a single individual at the patent office. This streamlined prosecution profile is typical for companies with highly targeted patenting goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706622 | USE OF LOW MOLECULAR WEIGHT HYALURONIC ACID FOR THE TREATMENT OF LUNG MUCOSAL INFLAMMATION | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706622 | USE OF LOW MOLECULAR WEIGHT HYALURONIC ACID FOR THE TREATMENT OF LUNG MUCOSAL INFLAMMATION | GALSTER, SAMUEL LEONARD | 1693 | §102§103DP | Non-Final OA | — | Pending | May 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial